Novartis, Mylan Settle Feud Over Generic Vivelle-Dot

By Amanda Bransford · November 21, 2011, 7:09 PM EST

Drugmakers Novartis AG and Mylan Inc. have settled patent litigation over Mylan's bid to produce a generic version of Novartis' estrogen therapy drug Vivelle-Dot, which will allow the generic to be...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Vivelle Ventures LLC et al v. Mylan Technologies, Inc. et al

Case Number

Court

New York Southern

Nature of Suit

Patent

Date Filed

February 22, 2011

Case Title

Vivelle Ventures LLC et al v. Mylan Technologies, Inc. et al

Case Number

Court

Vermont

Nature of Suit

Patent

Date Filed

February 24, 2011

Recent Articles By Amanda

July 16, 2012
Mayer Brown Tells 7th Circ. $17M Malpractice Suit Is Absurd
June 04, 2012
High Court Refuses Ex-Ala. Governor's Appeal In Bribery Case
May 30, 2012
DC Circ. Tells Armey To Take Up Medicare Beef With Insurer
May 14, 2012
High Court Won't Hear CUNA Retirees' Health Benefit Appeal
May 11, 2012
Insurers Deny They Owe Costs For Mining Co.'s Asbestos Feuds
April 16, 2012
UnitedHealth, Lexington End Coverage Feud In 1st Circ.
April 13, 2012
Continental Wants Limits On Asbestos Coverage For Mead
March 21, 2012
Insurers Stuck In Asbestos Duty-To-Defend Suit
March 16, 2012
Federal Plan To Share Health Insurance Risk Is Released
March 07, 2012
Amgen Seeks High Court Review Of Investor Class Cert.